LUMICKS Announces Adoption of z-Movi Cell Avidity Analyzer by Two Major Centres for Cancer Immunology
AMSTERDAM, Jan. 10, 2022 /PRNewswire/ -- LUMICKS, a next generation life science tools provider, today announced that two major centers of excellence in cancer immunology have adopted LUMICKS'
Source: finanznachrichten.de